ADVERTISING FEATURE
The new analyser was officially unveiled at EuroMedLab 2023 in Rome at the end of May.
Beckman Coulter’s Access NT-proBNP assay measures concentrations of N-terminal pro B-type natriuretic peptide that originate in a person’s heart. High levels of natriuretic peptides can indicate heart failure. Access NT-proBNP provides rapid results in less than 11 minutes and increases accuracy in diagnosing heart failure with age-based cut offs and disease-specific comorbidity data for improved test result interpretation.
Evaluation
An early evaluator of the DxI 9000, Dr Pamela Christudoss, Professor and Head, Department of Clinical Biochemistry, Christian Medical College Vellore, India noted: “Like clinical laboratories worldwide, we are running more tests than any time in our history. The innovations packed into the DxI 9000 will enable laboratories across the globe to improve their throughput rates and turnaround times with worldclass precision. In particular, the team loved the un-paralleled Zero Daily Maintenance especially for a platform that runs 450 tests per hour.”
An additional evaluator, Mr Ray
Divilley, Chief Medical Officer, Mayo University Hospital, Ireland, added: “With the DxI 9000, Beckman Coulter has successfully produced a platform that addresses today’s laboratories needs for speed, accuracy, and reliability. Based on our use and evaluation of the system in our laboratory, we were able to get actionable results back quicker to doctors and ultimately patients as they consider treatment options.
“Now we have no daily maintenance and weekly maintenance only takes 12 minutes, it allows the analyser to be up and running faster. Not only that, but we’ve also seen that the precision of the internal quality control over a period of a few months is consistently good, even with no daily maintenance.” “The DxI 9000 from Beckman Coulter allows staff to be confident that they can produce accurate and reliable results consistently. We can also process the
volume of work efficiently and we can get the results back as quick as possible. It is important in our profession to provide the correct results to the patient.” Another scientist involved in the evaluation at Mayo General Hospital was Senior Medical Scientist Sarah Ní Shúilleabháin. She commented: “It is a pressurised environment. You have lots of samples to get through in the day. You want the least amount of problems and least amount of downtime. The DxI 9000 from Beckman Coulter is very good in the sense that maintenance is minimal. Replenishing consumables in the morning and running your QC is both the top and bottom of it for daily set up, weekly maintenance is minimal, the fact that it has no daily maintenance is amazing.” “The key performance indicators that we use to ensure that we’re providing a quality service, one of them is the turnaround time. Immunoassays tend to be the longer, more time-consuming assays. On the DxI 9000 from Beckman Coulter reaction times are faster, that means that our results are out quicker. That means that the clinician and our clinical colleagues get the results faster. Say, for example, for assays such as a troponin I, used in the diagnosis of myocardial infarction, to have that result issued quickly is paramount.” Another staff member at Mayo General Hospital is Niamh O Mahony, Medical Scientist who was particularly impressed with the ease of use and speed offered by the DxI 9000. “The DxI 9000 has a new modern interface. It’s sleek, you have tiles that lay out your different sections, your consumables, reagents, calibrations, QC and your samples, so it’s very easy to find everything,” she commented.
WWW.PATHOLOGYINPRACTICE.COM JUNE 2023
“With the zero maintenance, we’ve less downtime and we can run more samples throughout the day. Patients have better turnaround times and better- quality care. We can relay results faster. The new substrate is a big deal: faster assays with more sensitive and precise performance - the detection capabilities give us such confidence in the results.”
Summary
Summing up, Heather Read-Harper, Senior European Product Manager for Clinical Diagnostics at Beckman Coulter Diagnostics had this to say: “The launch of the DxI 9000 Access Immunoassay Analyzer represents a very exciting time for Beckman Coulter. With this new analyser, we have introduced many new innovations to help optimise patient care and improve operator experience. Just one example is our patented PrecisionVision technology. This innovative feature monitors all critical processes in real time, delivering confidence in every result. With the addition of DxI 9000 to our already extensive portfolio, we can optimise laboratory performance and deliver tailored diagnostic solutions for hospitals, reference laboratories and physician office settings around the world.”
The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.
Beckman Coulter Diagnostics 01494 441181
infouk@beckman.com
https://www.beckmancoulter.com/en/
products/immunoassay/dxi-9000-access- immunoassay-analyzer
7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
